ライフサイエンスコーパス: interleukin

1 Instead, it is determined by competition for interleukins.

2 Interleukin 1 (IL-1) receptor-associated kinases (IRAKs)

3 lation of the neuroimmunomodulating cytokine interleukin 1 beta.

4 h their role in Toll-like receptor (TLR) and interleukin 1 receptor (IL-1R) mediated signaling pathwa

5 ctivate downstream signaling via TIRAP (Toll-interleukin 1 receptor domain containing adaptor protein

6 ic brain injury, and to evaluate the role of interleukin-1 (IL-1) signaling as a target for pharmacol

7 DCs are defined by their ability to release interleukin-1 (IL-1) while maintaining cell viability, e

8 Interleukin-1 (IL-1), an important proinflammatory cytok

9 matory interleukin-6 (IL-6) expression after interleukin-1 beta (IL-1beta) stimulation.

10 lammatory mediators include cytokines of the interleukin-1 family, such as IL-1alpha and IL-1beta.

11 members of the Toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) families transduce signal

12 esponses by targeted degradation of the Toll/interleukin-1 receptor (TIR) domain-containing adaptor p

13 Mutations and deletions of the interleukin-1 receptor accessory protein like 1 (IL1RAPL

14 culating levels of C-reactive protein (CRP), interleukin-1 receptor antagonist (IL-1Ra), and soluble

15 py efficacy stemmed from the upregulation of interleukin-1 receptor antagonist and suppression of MDS

16 chemoattractant protein-1, resistin, soluble interleukin-1 receptor I, soluble interleukin-2 receptor

17 Interleukin-1 receptor type I knockout mice, which displ

18 pathway involving the MyD88 adapter and the interleukin-1 receptor-associated kinase (IRAK) complex.

19 main containing adaptor protein)-MyD88-IRAK (interleukin-1 receptor-associated kinase)1/4-TRAF6 (TNF

20 ide primarily protects mice by repressing an interleukin-1- and 12/15-lipoxygenase-dependent neutroph

21 tokines that are orthologs of human cellular interleukin 10 (cIL-10).

22 Interleukin 10 (IL-10) is an anti-inflammatory cytokine

23 Cell wall peptidoglycan stimulates interleukin 10 (IL-10) production in Staphylococcus aure

24 Exposure of Interleukin 10 (il10)-deficient mice to cigarette smoke

25 creened the gamma interferon (IFN-gamma) and interleukin-10 (IL-10) responses to 6 HCMV peptide pools

26 Interleukin-10 (IL-10)-producing B cells (B10 cells) pla

27 We have previously shown that interleukin-10 (IL10) suppresses pressure overload-induc

28 Gene expression of interleukin-10, an immune-modulatory cytokine, was signi

29 consisting of interleukin-6, interleukin-8, interleukin-10, and fractalkine was identified to be the

30 and 3) selective secretion of interleukin-6, interleukin-10, and vascular endothelial growth factor t

31 egulatory B-cell-associated surface markers, interleukin-10, chemokine receptors, and immunoglobulin

32 application, secreting human proinsulin and interleukin-10, cured 66% of mice with new-onset diabete

33 Interleukin-6, interleukin-8, interleukin-10, interleukin-18, and tumor necrosis facto

34 bdaR1 subunit, specific for IFN-lambdas, and interleukin-10Rbeta (IL-10Rbeta), which is shared by mul

35 ceptor engagement but not following combined interleukin-12 (IL-12) and IL-18 stimulation.

36 aracterized by the significant production of interleukin-12 (IL-12) and IL-6.

37 ever, inborn errors in STAT4, which controls interleukin-12 (IL-12) responses, have not yet been repo

38 binds the p40 subunit of interleukin-23 and interleukin-12 and thereby blocks the activity of these

39 al had higher levels of TNF-alpha, IL-1beta, interleukin 12p70; CCL2, CCL4, CCL13, CCL17, CXCL8, CXCL

40 ory cytokines (interleukin-3, interleukin-6, interleukin-13, interleukin-17, macrophage inflammatory

41 values areas under the curve >0.70 including interleukin 15.

42 pleted blood lymphocytes and increased serum interleukin-15 (IL-15).

43 ing IFN-gamma, and was mimicked by exogenous interleukin-15 (IL-15).

44 ing CT-defined small airway abnormality, and interleukin-15 and interleukin-8 concentrations.

45 nce of small airway abnormality on CT, lower interleukin-15 concentrations, and higher interleukin-8

46 Interleukin-15 is a pleiotropic cytokine that is critica

47 after HSCT and favored by the high levels of interleukin-15 present in patients' sera, immature NK ce

48 ence of caspase-3 activity of hepatocellular interleukin 16 (IL-16) is no longer processed and releas

49 are: Interferon Stimulated Gene 15 (ISG15), Interleukin 16 (IL16), 2',5'-Oligoadenylate Synthetase L

50 Here, we tested the hypothesis that interleukin 17 (IL-17) and tumor necrosis factor (TNF) a

51 reflected by heightened interferon gamma and interleukin 17 (IL-17) production as well as by high lev

52 ith ex vivo screening, and was essential for interleukin-17 A (IL-17A)-mediated cross-reactivity and

53 cells was seen with increased expression of interleukin-17 and interleukin-22 by day 5 after injury.

54 Inhibition of interleukin-23 and interleukin-17 may have a role in the management of LAD1

55 nterleukin-3, interleukin-6, interleukin-13, interleukin-17, macrophage inflammatory proteins-1alpha,

56 iting interleukin-23-dependent production of interleukin-17.

57 at we detected had an increased frequency of interleukin 17A production compared with responses of T

58 tear levels of the proinflammatory cytokine interleukin 17A were significantly reduced in the krill

59 kin2, tumor necrosis factor alpha) and Th17 (interleukin 17A) cells compared with NIP children.

60 Th1 and Th17 cytokines interferon-gamma and interleukin 17A, and are unresponsive to in vitro PD-1 b

61 Donor T-cell-derived interleukin-17A (IL-17A) can mediate late immunopatholog

62 tection was associated with the induction of interleukin-17A (IL-17A), IL-22, and gamma interferon (I

63 trinsic role in promoting both IFN-gamma and interleukin-17A production during infection with C. rode

64 -) mice were given injections of recombinant interleukin 18 (rIL18) or saline (control) during DSS ad

65 MAIT cells was dependent on monocyte-derived interleukin 18, and was reduced in patients with HCV inf

66 ts through larger increases in RE, PGLO, and interleukin-18 but without impacting the RAAS.

67 on-beta production and gasdermin D-dependent interleukin-18 secretion.

68 Apart from urine clusterin and interleukin-18, all other urinary biomarkers were elevat

69 nterleukin-6, interleukin-8, interleukin-10, interleukin-18, and tumor necrosis factor-R2 were each s

70 o immunomodulatory therapeutics.The cytokine interleukin 1alpha (IL-1alpha) plays an important role i

71 MABp1, an antibody that targets interleukin 1alpha, has been associated with antitumour

72 Only interleukin-1alpha possibly fulfills the criteria which

73 With the exception of interleukin-1alpha, none of the humoral factors changed

74 Interleukin-1alpha, when normalized to baseline, increas

75 gnificant difference was detected: Levels of interleukin 1beta (IL-1beta) were lower in dengue-infect

76 Secretion of interleukin 1beta (IL-1beta), in response to inflammasom

77 nal tumor necrosis factor-alpha (TNF-alpha), interleukin 1beta (IL-1beta), intracellular adhesion mol

78 es (controls) and analyzed expression NLRP3, interleukin 1beta (IL1B, in plasma), and IL18 (in plasma

79 riate analyses adjusting for covariates IL6, interleukin 1beta (IL1beta), and interleukin 1Ralpha (IL

80 active protein (CRP), tumor necrosis factor, interleukin 1beta, 6, and 10, leukocyte telomere length,

81 roinflammatory cytokines (eg, interleukin 6, interleukin 1beta, and tumor necrosis factor alpha) in c

82 (qRT-PCR), and the proinflammatory cytokines interleukin 1beta, interferon beta, and RANTES (regulate

83 ealed increased transcriptional induction of interleukin 1beta, interferon beta, and RANTES in ZIKV-i

84 e CNS, Rag1(-/-) mice showed lower levels of interleukin 1beta, reduced microglial proliferation, and

85 atory (NLR family pyrin domain containing 3, interleukins 1beta and 6, and cysteine-cysteine chemokin

86 lating lipopolysaccharide and NLRP3-mediated interleukin-1beta (IL-1beta) secretion.

87 Interleukin-1beta (IL-1beta), an inflammatory cytokine a

88 There is a strong link between integrins and interleukin-1beta (IL-1beta), but the specifics of the r

89 ytes expressed the pro-inflammatory cytokine interleukin-1beta (IL-1beta).

90 nal immunopathology (neutrophil recruitment, interleukin-1beta [IL-1beta] secretion, and lactate dehy

91 vity was evaluated by measuring the level of interleukin-1beta and -18 in the supernatants of activat

92 eased concentrations of active caspase-1 and interleukin-1beta are related to an increased concentrat

93 1- and CD3-positive cells, the production of interleukin-1beta by CD11b- and Iba-1-positive cells, an

94 ndocytosis, ROS generation and increases pro-interleukin-1beta expression in macrophages.

95 its release of the pro-inflammatory cytokine interleukin-1beta from activated microglia, consistent w

96 h ATP, led to an activation of caspase 1 and interleukin-1beta in P2X7-competent macrophages.

97 (CANTOS), a randomised trial of the role of interleukin-1beta inhibition in atherosclerosis, with th

98 roptosis, as measured by caspase-1-dependent interleukin-1beta release, though this phenotype could b

99 d an increase in NLRP3 inflammasome-mediated interleukin-1beta secretion.

100 expression, caspase 1 activity, or IL-1beta (interleukin-1beta) protein expression under in vivo and

101 cytokines/chemokines in the brain, including interleukin-1beta, interferon-gamma, and fractalkine as

102 ZDF islets contain elevated levels of CB1R, interleukin-1beta, tumor necrosis factor-alpha, the chem

103 nd upregulation of pro-inflammatory cytokine interleukin-1beta.

104 riates IL6, interleukin 1beta (IL1beta), and interleukin 1Ralpha (IL1Ralpha) were associated with inc

105 Interleukin 2 (IL-2) promotes Foxp3(+) regulatory T (Tre

106 tumor necrosis factor alpha (TNF-alpha), and interleukin 2 (IL-2) secretion by CD8(+) T cells.

107 or [gammadelta-TCR]) and cytokines examined (interleukin 2 [IL-2], IL-4, IL-10, IL-17A, and gamma int

108 Infection decreased interleukin 2 and interferon gamma production as well as

109 CCL2, CCL4, CCL13, CCL17, CXCL8, CXCL10; and interleukin 2 and interferon gamma than children who sur

110 and CD8+ T cells and a higher proportion of interleukin 2-secreting cells (P = .01 and P = .002, res

111 compared to CD8(+) T cells) that coexpressed interleukin-2 (IL-2) (66.4%) and/or tumor necrosis facto

112 We found that aspects of the interleukin-2 (IL-2)-sensitive effector gene program in

113 us infusion of autologous TILs and high-dose interleukin-2 [720 000 IU/kg] every 8 h).

114 Measurements of model cytokine interleukin-2 concentrations from <20 fM to >200 pM were

115 The absence of the Tec family kinase Interleukin-2 inducible T cell kinase (Itk) results in T

116 n, soluble interleukin-1 receptor I, soluble interleukin-2 receptor alpha, and tumor necrosis factor

117 tandard induction immunosuppression was with interleukin-2 receptor antagonists, and antithymocyte gl

118 PREX1-Rac1-signaling pathway that stabilizes interleukin-2(IL-2), IL-4, and IL-10 messenger RNA (mRNA

119 cells, by enhancing their responsiveness to interleukin-2.

120 efficacy of CD20-targeted therapy, we fused interleukin 21 (IL-21), which induces direct lymphoma cy

121 se 1 dose-escalation study of membrane-bound interleukin 21 (mbIL21) expanded donor NK cells infused

122 ), CD4+IL17A+ cells (P < .01), and CD4+CXCR5+interleukin 21+ follicular T-helper (Tfh) cells (P < .01

123 found that a small subset of gp120-specific interleukin-21 (IL-21)-secreting CXCR5(+) CD4(+) T cells

124 was an inverse association between levels of interleukin 22 and serum levels of tryptophan.

125 Serum concentration of interleukin 22 associated with disease activity in patie

126 We measured levels of interleukin 22 in serum from 28 patients by enzyme-linke

127 Interleukin-22 (IL-22) plays an important role in host i

128 g HFD with inulin restored microbiota loads, interleukin-22 (IL-22) production, enterocyte proliferat

129 h increased expression of interleukin-17 and interleukin-22 by day 5 after injury.

130 Levels of interleukin 23 (IL23) and T-helper (Th) 17 cell pathway

131 onoclonal antibody that selectively inhibits interleukin 23 (IL23), a cytokine implicated in the path

132 ty, humanised, IgG1 kappa antibody targeting interleukin 23 p19 that represents an evolving treatment

133 t dominates the binding affinity for an anti-interleukin-23 (anti-IL-23) antibody by using the comple

134 Interleukin-23 (IL-23), an IL-12 family cytokine, plays

135 b, an antibody that binds the p40 subunit of interleukin-23 and interleukin-12 and thereby blocks the

136 Inhibition of interleukin-23 and interleukin-17 may have a role in the

137 The interleukin-23 pathway is implicated genetically and bio

138 Therefore, selective blockade of interleukin-23 via inhibition of p19 might be a viable t

139 In this phase 2 trial, selective blockade of interleukin-23 with risankizumab was associated with cli

140 the activity of these cytokines, inhibiting interleukin-23-dependent production of interleukin-17.

141 show that BST-2 upregulation by IFN-beta and interleukin-27 (IL-27) also increases the surface expres

142 egulatory T cells (Tr1 cells) are induced by interleukin-27 (IL-27) and have critical roles in the co

143 Interleukin-27 (IL-27) and IL-37 are two known anti-infl

144 is demonstrate that plasma levels of soluble interleukin-27 (IL-27) are significantly elevated in ind

145 , we show that the immunoregulatory cytokine interleukin-27 is upregulated centrally and peripherally

146 ated in the interrogated traits, such as the interleukin-27 pathway in rheumatoid arthritis.

147 Here, the authors show interleukin-27 promotes the tissue-protecting functions

148 c-kit mutant Kit(W/W-v) mice indicated that interleukin-3 and c-Kit contribute to expulsion of the i

149 with transgenic expression of human GM-CSF, interleukin-3, and stem cell factor in a NOD/SCID-IL2Rga

150 ced production of proinflammatory cytokines (interleukin-3, interleukin-6, interleukin-13, interleuki

151 ibe a type 2 immune circuit where pancreatic interleukin-33 (IL-33) promotes insulin secretion via th

152 lammation (interleukin-6, interleukin-8, and interleukin-33 and soluble suppression of tumorigenicity

153 ipient microbiome, the impact of the alarmin interleukin-33 on alloreactivity, and the role of Notch

154 All biomarkers (with the exception of interleukin-33) were higher in both groups of matched ac

155 ngiopoietin-2, interleukin-6, interleukin-8, interleukin-33, and soluble suppression of tumorigenicit

156 T cells, we show that FLIL33, but not mature interleukin-33, physically interacts with IPO5 and that

157 d children with measles, and lower levels of interleukin 4 and 5.

158 n children who survived, and lower levels of interleukin 4.

159 was associated with exposure, with increased interleukin-4 (IL-4) production, IL-5 transcription, and

160 Of the cytokines examined, Ag-specific interleukin-4 (IL-4) T-helper enzyme-linked immunosorben

161 ergy expenditure in wild-type, Ucp1(-/-) and interleukin-4 receptor-alpha double-negative (Il4ra(-/-)

162 In vitro interleukin-4-polarization of human primary monocytes in

163 Serum interleukin 5 levels and eosinophil activation, as asses

164 Benralizumab is a humanised, anti-interleukin 5 receptor alpha monoclonal antibody that di

165 Benralizumab is an anti-eosinophilic, anti-interleukin-5 receptor alpha monoclonal antibody that ha

166 dy directed against the alpha subunit of the interleukin-5 receptor that significantly reduces the in

167 , variable levels of CCR3, and low levels of interleukin-5Ralpha.

168 ological mechanical damage, via induction of interleukin 6 (IL-6) from epithelial cells, tailored eff

169 describe a new mouse strain, in which human interleukin 6 (IL-6) gene encoding the cytokine that is

170 The cellular sources of interleukin 6 (IL-6) that are relevant for differentiati

171 ding protein (I-FABP), soluble CD14 (sCD14), interleukin 6 (IL-6), and C-reactive protein (CRP) at 6

172 of matrix metalloproteases and synthesis of interleukin 6 (IL-6).

173 re; Egfr(f/f) mice had reduced expression of interleukin 6 (IL6), and epithelial STAT3 activation was

174 ripheral blood mononuclear cells and reduced interleukin 6 (P = .028) and GVHD biomarkers (Reg3, P =

175 red parasite biomass, systemic inflammation (interleukin 6 [IL-6]), endothelial activation (angiopoie

176 pondin 2; intercellular adhesion molecule 1; interleukin 6 [IL-6]; stromal cell-derived factor 1; tis

177 ssociated among HIV-infected men with higher interleukin 6 and high-sensitivity C-reactive protein an

178 e synthase, tumor necrosis factor-alpha, and interleukin 6).

179 ft ventricular hypertrophy, glycemic traits, interleukin 6, and circulating lipids.

180 D5Rs (DRD5KO mice) to show that carrageenan, interleukin 6, as well as BDNF-induced hyperalgesia and

181 The following measurements were obtained: interleukin 6, high-sensitivity C-reactive protein, solu

182 ed SAMHD1 and proinflammatory cytokines (eg, interleukin 6, interleukin 1beta, and tumor necrosis fac

183 control mice, but this effect was delayed in interleukin 6-deficient mice.

184 idine triphosphate nucleotidohydrolase in an interleukin 6-independent manner.

185 erformed studies with C57Bl6-J (control) and interleukin 6-knockout mice.

186 ion of XBP1, and that this activity requires interleukin 6.

187 y weight, and elevated levels of circulating interleukin 6.

188 nary hypertension in rats (n=8) and elevated interleukin 6.

189 specific enolase: area under the curve=0.69; interleukin 6: area under the curve=0.82).

190 pendent on exogenous soluble factors such as interleukin-6 (IL-6) and APRIL, to prevent their cell de

191 naling mediator of many cytokines, including interleukin-6 (IL-6) and IL-10.

192 they were used for the selective capture of interleukin-6 (IL-6) as targeted antigen.

193 erclonal communication mechanism mediated by interleukin-6 (IL-6) cytokine secreted from EGFRvIII-pos

194 ilage explants, suppressing pro-inflammatory interleukin-6 (IL-6) expression after interleukin-1 beta

195 n of tumor necrosis factor alpha (TNF-alpha)/interleukin-6 (IL-6) in infected kidneys.

196 used infiltration of the peripheral cytokine interleukin-6 (IL-6) into brain parenchyma and subsequen

197 ons of FITC-dextran gut translocation, serum interleukin-6 (IL-6) levels, bacteremia, and sepsis mort

198 PB interleukin-6 (IL-6) negatively correlated with endothel

199 se of keratinocyte-derived cytokine (KC) and interleukin-6 (IL-6) production by cells.

200 expression of the pro-inflammatory cytokine interleukin-6 (IL-6) relative to BALB/cJ and PDE11A WT m

201 Interleukin-6 (IL-6) was identified as a regulator of mI

202 The inflammatory cytokine, interleukin-6 (IL-6), is a critical mediator of HCC deve

203 er levels of tumor necrosis factor (TNF) and interleukin-6 (IL-6), more neutrophil recruitment, and a

204 is associated with poor survival in HCC and interleukin-6 (IL6) expression.

205 tic livers of beta2SP(+/-) mice treated with interleukin-6 (pIL6; (IL6) beta2SP(+/-) LSCs) were highl

206 igher AT1RaAbs correlated significantly with interleukin-6 (Spearman r=0.33, P<0.0001), systolic bloo

207 h controls for the proinflammatory cytokines interleukin-6 and interleukin-8.

208 Higher average maternal interleukin-6 concentration during pregnancy was prospec

209 ated the association between higher maternal interleukin-6 concentrations and lower impulse control.

210 reening was cardiotrophin-1, a member of the interleukin-6 family.

211 Interleukin-6 is a cytokine critical to proinflammatory

212 es to map integratively the epitope of human interleukin-6 receptor (IL-6R) for two adnectins with di

213 -1 receptor antagonist (IL-1Ra), and soluble interleukin-6 receptor (sIL-6R).

214 uated glutamate uptake, intramyelinic edema, interleukin-6 release, complement activation, inflammato

215 Interleukin-6 significantly correlated with alveolar bon

216 ological indicator of maternal inflammation (interleukin-6) that has been shown to influence fetal br

217 e expression of tumor necrosis factor alpha, interleukin-6, and interleukin-8 in the respiratory trac

218 prostaglandin E2, epinephrine, TNFalpha, and interleukin-6, and the neuropathic pain induced by the c

219 al, and cardiometabolic factors, and CRP and interleukin-6, each standard deviation increase in sCD14

220 tive catalase; and 3) selective secretion of interleukin-6, interleukin-10, and vascular endothelial

221 of proinflammatory cytokines (interleukin-3, interleukin-6, interleukin-13, interleukin-17, macrophag

222 al injury (angiopoietin-2) and inflammation (interleukin-6, interleukin-8, and interleukin-33 and sol

223 A group consisting of interleukin-6, interleukin-8, interleukin-10, and fracta

224 Interleukin-6, interleukin-8, interleukin-10, interleuki

225 ducts, surfactant protein D, angiopoietin-2, interleukin-6, interleukin-8, interleukin-33, and solubl

226 er N-acetyl-l-cysteine reduced the levels of interleukin-6, interleukin-8/C-X-C motif chemokine ligan

227 , midregional proadrenomedullin, cystatin-C, interleukin-6, procalcitonin, and others.

228 ion, high-sensitivity C-reactive protein and interleukin-6, when the birds were adults.

229 ), a linchpin in the pre-B-cell receptor and interleukin 7 receptor signaling pathways critical to B-

230 Interleukin-7 (IL-7) availability determines the size an

231 meostatic proliferation of infected cells by interleukin-7 (IL-7) or antigenic stimulation, as well a

232 ression of multiple hematopoietic cytokines (interleukin-7 [IL-7], Flt3L, stem cell factor [SCF], ThP

233 were associated with increased expression of interleukin 8 (IL-8), CXCL2, IL-1beta, tumor necrosis fa

234 ection were assessed by measuring release of interleukin 8 from AGS cells (to detect cag pathogenicit

235 ed LPS-induced inflammation, as monitored by interleukin 8 production.

236 ered genes include humanin-like-8 (MTRNRL8), interleukin-8 (IL8), and serpin peptidase inhibitor, cla

237 pressing gingipain-associated degradation of interleukin-8 (IL8).

238 er interleukin-15 concentrations, and higher interleukin-8 concentrations, than were no acute exacerb

239 l airway abnormality, and interleukin-15 and interleukin-8 concentrations.

240 spholipase A2; at CYP2F1, with higher plasma interleukin-8 concentrations; at TREH, with lower concen

241 eterious non-synonymous SNPs (nsSNPs) in the interleukin-8 gene using three steps.

242 or necrosis factor alpha, interleukin-6, and interleukin-8 in the respiratory tract and central nervo

243 opoietin-2) and inflammation (interleukin-6, interleukin-8, and interleukin-33 and soluble suppressio

244 ssion model incorporating oxygenation index, interleukin-8, and tumor necrosis factor-R2 was superior

245 A group consisting of interleukin-6, interleukin-8, interleukin-10, and fractalkine was ident

246 Interleukin-6, interleukin-8, interleukin-10, interleukin-18, and tumor

247 nt protein D, angiopoietin-2, interleukin-6, interleukin-8, interleukin-33, and soluble suppression o

248 ivariable analysis included higher levels of interleukin-8, monocyte chemoattractant protein-1, resis

249 proinflammatory cytokines interleukin-6 and interleukin-8.

250 ysteine reduced the levels of interleukin-6, interleukin-8/C-X-C motif chemokine ligand 8, and monocy

251 severity, including JAK/STAT, prolactin, and interleukin 9 signaling.

252 T cells lacking Atg3 or Atg5 have increased interleukin-9 (IL-9) expression upon differentiation int

253 ow that, in mice and humans, a population of interleukin-9 (IL-9)-producing T cells activated via the

254 ts most likely to benefit from targeted anti-interleukin and anti-immunoglobulin E therapies, and in

255 Serum tumor necrosis factor-alpha, interleukins, hemogram, and liver and renal function tes

256 rvastatin was able to block the induction of interleukins IL-6 and IL-8 triggered by pathologic stimu

257 ion of proinflammatory biomarkers, including interleukin (IL) 1beta, tumor necrosis factor alpha (TNF

258 study evaluates whether specific patterns of interleukin (IL)-1 gene variants, known to affect period

259 Increasing evidence has linked dysregulated interleukin (IL)-10 production by IL-10(+ve) B cells to

260 TRIF was required for induction of interleukin (IL)-10, IL-6, and IL-1beta cytokines.

261 Interleukin (IL)-12 activity is involved in the pathogen

262 Swift production of interleukin (IL)-12 by tissue-resident XCR1(+) conventio

263 Increased level of proinflammatory cytokine interleukin (IL)-12 correlates with the severity of peri

264 says quantified tumor necrosis factor (TNF), interleukin (IL)-12, and IL-10 in gingival tissues.

265 Levels of interleukin (IL)-13 in BAL were also significantly decre

266 Interleukin (IL)-13 is a pleiotropic T helper type 2 cyt

267 Interleukin (IL)-15 is a pleiotropic cytokine, which is

268 STAT5 at the promoter of Id2 in response to interleukin (IL)-15.

269 the effects of lipopolysaccharides (LPS) and interleukin (IL)-17A on the activation of macrophages in

270 HIV/HCV coinfection and elevated interleukin (IL)-18 levels are both associated with enha

271 olume, and total amount and concentration of interleukin (IL)-1beta in GCF.

272 Interleukin (IL)-1beta levels were significantly higher

273 treated with anakinra, an antagonist of the interleukin (IL)-1beta receptor (IL-1R), or harboring a

274 ession of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6 in the synovial membran

275 ancer risk associated with concentrations of interleukin (IL)-1beta, IL-2, IL-6, IL-8, IL-10, IL-12,

276 molars were collected for quantification of interleukin (IL)-1beta, IL-4, IL-6, IL-17, and tumor nec

277 iants include polymorphisms in the genes for interleukin (IL)-1beta, IL-6, IL-10, monocyte chemoattra

278 Interleukin (IL)-1beta, osteoprotegerin (OPG), and bone-

279 gamma, tumor necrosis factor (TNF)-alpha and interleukin (IL)-2, but not IL-17A; iii) high-affinity M

280 Interleukin (IL)-27, a member of the IL-12 cytokine fami

281 Increased expression of Interleukin (IL)-33 has been detected in intestinal samp

282 DOX treatment not only increases interleukin (IL)-33 released from breast tumor cells, wh

283 (MSC) numbers, type 2-associated cytokines (interleukin (IL)-33, thymic stromal lymphopoietin, IL-5

284 trated the role of interferon (IFN)gamma and interleukin (IL)-4 in polarizing these cells towards a M

285 Arg1 and Il10 mRNA expression and decreased interleukin (IL)-4, IL10 and IL-13 protein levels.

286 bility to produce Th2-type cytokines such as interleukin (IL)-5 and IL-13.

287 This is distinct from the response evoked by interleukin (IL)-6 that is known to induce both pro infl

288 flammatory cytokines: tumor necrosis factor, interleukin (IL)-6, and reactive oxygen species.

289 eased interferon-gamma-inducible protein 10, interleukin (IL)-6, IL-8, vascular endothelial growth fa

290 We recently showed that interleukin (IL)-6-type cytokine signaling in adipocytes

291 of transforming growth factor (TGF) beta and interleukin (IL)-8.

292 s in mice stimulated secretion of cytokines (interleukin [IL] 25, IL33, and thymic stromal lymphopoie

293 As associated with a type 2 immune response (interleukin [IL]5 gene, IL13, and IL13RA2) and a type 17

294 K-2 induced the expression of CCL4, CCL5 and interleukin(IL)-1beta in HD11 cells and CCL4 and CCL5 in

295 gut homeostasis through the immunomodulatory interleukin IL10, but there is little knowledge on how t

296 ha-induced, but not Toll-like receptor 4- or interleukin-induced, NF-kappaB activation.

297 ns naturally emerge from the balance between interleukins production and consumption.

298 al multidomain structure: an N-terminal Toll-interleukin receptor (TIR) or coiled-coil (CC) domain, a

299 common gamma chain, which is part of several interleukin receptors, including IL-2 and IL-7 receptors

300 d multiple BHRF1-2 miRNA targets involved in interleukin signaling pathways.